How Pfizer and Allergan's Merger Got Busted By Washington | Summary and Q&A

TL;DR

The U.S. Treasury Department's new regulations resulted in the cancellation of the planned Pfizer-Allergan merger due to tax inversion concerns.

Key Insights

• 👶 The Pfizer-Allergan merger was blocked due to the U.S. Treasury Department's new regulations on tax inversions.
• 😚 The government's concern about losing tax revenue and the potential anti-trust issues contributed to the deal's downfall.
• 🥺 Allergan investors might have undervalued the company, leading to doubts about the deal's success.
• 🤝 Pfizer and Allergan strategically structured the deal to stay below the ownership threshold required for a successful tax inversion.
• 😀 The regulations highlighted the challenges faced by companies attempting tax inversions and the risks involved in complex multinational mergers.
• 🚕 The Treasury Department aimed to close the tax loophole used by foreign companies to reduce their tax burden by acquiring U.S. companies.
• 🤝 The canceled deal had significant financial implications for both Pfizer and Allergan, affecting their future growth strategies.

Transcript

Kristine Harjes: Todd, I don't know about you, but I have been racking my brain all morning for breakup songs. Todd Campbell: I think this is the biggest breakup since Bennifer. Harjes: This might be the biggest healthcare news we've had all year so far. Campbell: Pfizer likes to make the big news, don't they? They did it last fall by announcing th... Read More

Questions & Answers

Q: What were the reasons behind the blockage of the Pfizer-Allergan merger?

The U.S. government was concerned about losing tax revenue and had been implementing rules to prevent tax inversions. The new regulations specifically targeted the Pfizer-Allergan deal, effectively killing it.

Q: Why did Allergan, the smaller company, technically buy Pfizer?

Allergan was attempting to skirt the Treasury's rules by appearing as the acquirer rather than the acquired. This allowed them to use the tax percentages of foreign countries, such as Ireland.

Q: What criteria needed to be met for a successful tax inversion?

U.S. company shareholders could not own more than 80% of the new entity after the deal. Ideally, the ownership should be below 60% to avoid tax penalties. Pfizer structured the deal to ensure their shareholders would own 56% of the merged entity.

Q: How did the new regulations discount Allergan's prior acquisitions?

The new rules discounted the value of Allergan's acquisitions in the past three years, leading to a reassessment of the company's size and impacting Pfizer's calculation to meet the ownership threshold.

Summary & Key Takeaways

• The proposed $160 billion Pfizer-Allergan deal would have created a company with $65 billion in sales and moved Pfizer's headquarters to Ireland for tax purposes.

• Allergan investors might have been underpricing the company, leading to doubts about the deal's success.

• The U.S. Treasury Department's new regulations aimed at stopping tax inversions dealt a fatal blow to the merger.